Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Company
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 06/11 10:59:49 am
516.8 DKK   +0.25%
06/10NOVO NORDISK  : Goldman Sachs keeps its Buy rating
MD
06/10NOVO NORDISK  : Bernstein gives a Buy rating
MD
06/10NOVO NORDISK  : JP Morgan keeps its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- products for treating diabetes and obesity (84.3%);

- hemophilia treatment products (8.4%): mainly injections of protein;

- growth hormones (6%): used for treatment of growth deficiencies in children;

- hormone replacement products (1.3%): used for treatment of the menopause and prevention of osteoporosis.

Net sales are distributed geographically as follows: Europe (19.1%), the United States (47.1%), North America (2.5%), Africa/Asia/Middle East/Oceania (11.5%), China (10.5%), Japan and Korea (5.3%) and Latin America (4%).

Number of employees : 45 323 people.
Sales per Business
20192020Delta
DKK (in Million)%DKK (in Million)%
Diabetes and Obesity Care102,84084.3%108,02085.1% +5.04%
Biopharm19,18115.7%18,92614.9% -1.33%
Sales per region
2020
DKK (in Million)%
United States57,82445.6%
EMEA34,29727%
Rest of the World17,44813.7%
China14,08411.1%
Canada3,2932.6%
Managers
NameAgeSinceTitle
Lars Fruergaard Jorgensen542017President & Chief Executive Officer
Karsten Munk Knudsen492018Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen60-Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff502019Executive VP & Head-Information Technology
Stephen Gough-2015Global Chief Medical Officer
Maziar Mike Doustdar502016Executive Vice President-International Operations
Elizabeth Anne Hewitt642012Independent Director
Sylvie Louise Grégoire, Dr.592015Independent Director
Brian F. Daniels, Dr.612016Independent Director
Helge Lund582018Chairman
Members of the board
NameAgeSinceTitle
Helge Lund582018Chairman
Anne Marie Handrup Kverneland642000Director
Stig Strøbæk571998Director
Elizabeth Anne Hewitt642012Independent Director
Jeppe Fonager Christiansen612013Vice Chairman
Sylvie Louise Grégoire, Dr.592015Independent Director
Brian F. Daniels, Dr.612016Independent Director
Kasim Kutay552017Member-Supervisory Board
Mette Bøjer Jensen452018Director
Thomas Rantzau482018Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 537,000,000 0 0.0% 0 0.0% 69.8%
Stock B 1 1,772,564,000 1,612,733,341 91.0% 37,500,000 2.1%
Shareholders
NameEquities%
Novo Holdings A/S (Investment Company) 116,129,000 6.55%
Norges Bank Investment Management 43,498,435 2.45%
The Vanguard Group, Inc. 40,178,414 2.27%
Alecta Pension Insurance Mutual 27,085,444 1.53%
BlackRock Fund Advisors 26,690,203 1.51%
Fundsmith LLP 20,525,100 1.16%
BlackRock Investment Management (UK) Ltd. 18,388,805 1.04%
Capital Research & Management Co. (World Investors) 16,895,809 0.95%
Handelsbanken Fonder AB 15,721,299 0.89%
Flossbach von Storch AG 13,895,000 0.78%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 12,620,1920.71%931,300,254 USD
NNIT A/S (NNIT) 4,375,00017.5%77,105,088 USD
Innate Pharma (IPH) 9,817,54612.4%42,073,388 USD
Markets and indexes
-
- Main Market Large
- OMXC 20 / Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, PEA, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  NOVOB:DC
- Reuters Code :  NOVOb.CO
- Datastream Code :  DK:NON
Company contact information
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd


Phone : +45 44 44 88 88
Fax : +45 44 49 05 55
web site : http://www.novonordisk.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Novo Nordisk A/S
Sector Other Pharmaceuticals
1st jan.Capitalization (M$)
NOVO NORDISK A/S21.13%193 164
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857
ELI LILLY AND COMPANY32.72%203 704
MERCK & CO., INC.-6.76%193 120
ASTRAZENECA PLC13.87%154 435
BRISTOL-MYERS SQUIBB COMPANY8.56%150 360
AMGEN INC.5.59%139 484
SANOFI12.96%134 500
GLAXOSMITHKLINE PLC4.58%99 056
JIANGSU HENGRUI MEDICINE CO., LTD.-21.45%72 637
CHUGAI PHARMACEUTICAL CO., LTD.-20.44%65 563
ALLERGAN PLC0.97%63 659
BAYER AG11.04%63 542
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.64%53 877
DAIICHI SANKYO COMPANY, LIMITED-27.20%44 921
ASTELLAS PHARMA INC.20.98%32 631
EISAI CO., LTD.45.14%27 948